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Breathlessness, physical activity and
sustainability of healthcare
To the Editor:
We welcome the important paper by GRØNSETH et al. [1], which used data from the Burden of Obstructive
Lung Disease (BOLD) project to highlight the prevalence of breathlessness across the world. As well as
being significant because it is a source of suffering that should be ameliorated, we believe that attention to
breathlessness, particularly in midlife, has important implications for sustainable healthcare because it
allows timely diagnosis, would drive the promotion of physical activity, forms part of a strategy to reduce
the burden of comorbidities and would have beneficial environmental effects.
Ensuring that health systems remain sustainable requires the prevention of future ill health [2].
Breathlessness in an individual may or may not indicate the presence of disease, but if it triggers a timely
diagnosis of chronic obstructive pulmonary disease (COPD) or other conditions it offers the opportunity to
intervene at an early stage with evidence-based therapies including, in COPD, intensive smoking cessation
support, influenza vaccination and pulmonary rehabilitation [3]. Late presentation is a major concern in
COPD, with many patients not diagnosed until they are admitted to hospital with an acute exacerbation [4].
As the authors note, the data they collected could only account for 13% of the variance in dyspnoea [1]. Other
lung function parameters, such as transfer factor, have been shown to wield more prognostic power in COPD
than spirometry [5] but, even in an extensively characterised population of COPD patients, lung function and
other clinical parameters could explain only 32% of the variance in Medical Research Council score, with
transfer factor of the lung for carbon monoxide, residual volume/total lung capacity ratio and exacerbation
rate retained in a stepwise regression model [6]. Lung health screening in primary care confirms that
breathlessness is common and associated both with reduced self-reported physical activity and reduced
quadriceps strength, indicating the presence of deconditioning in healthy individuals as well as those
with abnormal spirometry [7]. Increase in physical activity in midlife is associated with improved survival [8]
and support to increase physical activity should be part of a structured approach to the management of
breathlessness, and given as much importance as the medical management of specific pathologies. An increase
in active transport (walking or cycling) is a key tool for promoting fitness and particularly desirable for
respiratory health, as increased physical activity may reduce lung function decline [9], while simultaneously
reducing the financial and carbon/climate change cost to the environment of transport generally, as well as
particulate emissions from car exhausts, which have specific noxious effects on lung health.
Finally, the need for concerted efforts to increase physical activity was highlighted in a recent UK Dept of
Health Framework document for the management of comorbidities [10]. Many patients with COPD have
comorbidities, including cardiovascular disease, diabetes, osteoporosis and anxiety, all of which may, to an
extent, be prevented or reversed by the promotion of physical activity in breathless individuals who have,
or may otherwise go on to develop, long-term conditions.
Attention to breathlessness in midlife has the potential to significantly improve the identification of early
disease and prevent the development of health problems, and would promote the sustainability at a social,
financial and environmental level that is needed to improve patient care today and enable systems to
deliver high-quality healthcare tomorrow.
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Low minimal inhibitory concentrations of
linezolid against multidrug-resistant
tuberculosis strains
To the Editor:
We are following the debate about the administration and the preferred dosage of linezolid in the
treatment of multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR) TB with
great interest. Linezolid is a high potent drug against M. tuberculosis, but its widespread use is limited due
to severe side-effects in long-term treatment, which often occurs after the usage of 600 mg twice a day in
bacterial disease for >28 days and mainly includes severe haematotoxic effects (i.e. myelosuppression,
anaemia, thrombocytopaenia) or polyneuropathy [1]. However, the current standards in MDR- and
XDR-TB require several months of treatment. In addition, the administration of 1200 mg linezolid per day
leads to high treatment costs, which limits the usage, especially in low-income countries [1, 2]. Lowering
the dosage of linezolid could, therefore, be an effective step towards reducing costs and severe side-effects.
In a letter from SOTGIU et al. [3], published in the European Respiratory Journal, the authors analysed a
subgroup of patients enrolled in their previous meta-analysis about the safety, efficacy and tolerability of
linezolid in the treatment of MDR-TB [1]. They found, in a crude statistical comparison of their results to
the findings by LEE et al. [4] who had provided prospective experimental data for the safety of linezolid in
the treatment of XDR-TB, that the best risk-benefit profile was a daily dose of ⩽600 mg [3]. This
suggestion was supported by three other studies, which showed some evidence that lower, but yet effective,
dosage of linezolid may reduce both toxicity and cost [2, 5, 6]. In this context, drug susceptibility testing is
necessary to determine efficacy of linezolid against a wide range of M. tuberculosis strains and could
provide a further rationale for the application of a lower dosage.
For this purpose we retrospectively evaluated the in vitro susceptibility test results of linezolid from clinical
routine assessment via minimal inhibitory concentrations (MICs) against 148 M. tuberculosis strains
including 18 MDR-TB strains isolated from patients treated in our centre from 2002 to 2012. Testing for
MIC was performed on solid Middlebrook-7H10 agar plates as described elsewhere [7]. MICs were defined
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